ChileTuberculosis profile
Population  2014 18 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.29 (0.28–0.29) 1.6 (1.6–1.6)
Mortality (HIV+TB only) <0.01 (<0.01–<0.01) 0.04 (0.03–0.05)
Prevalence  (includes HIV+TB) 3.5 (1.5–6.3) 20 (8.4–36)
Incidence  (includes HIV+TB) 2.8 (2.4–3.2) 16 (14–18)
Incidence (HIV+TB only) 0.13 (0.1–0.16) 0.73 (0.57–0.91)
         
Case detection, all forms (%) 85 (75–97)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 1.2 (0.68–2.1) 0.56 (0.01–3.1)
MDR-TB cases among notified pulmonary
TB cases
21 (12–36) 1 (0–7)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 1 481   158
Pulmonary, clinically diagnosed 237   15
Extrapulmonary 467   25
       
Total new and relapse 2 383    
Previously treated, excluding relapses 57    
Total cases notified 2 440    
Among 2 383 new and relapse cases:
53 (2%) cases aged under 15 years; male:female ratio: 1.8
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 1 127 (76%) 179 (70%) 1 365
Laboratory-confirmed RR-/MDR-TB cases     23
Patients started on MDR-TB treatment ***     10
TB/HIV 2014 Number (%)
TB patients with known HIV status 1 213 (50)
HIV-positive TB patients 213 (18)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART) 66 (31)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (47) 2 401
Previously treated cases, excluding relapse, registered in 2013 (5) 38
HIV-positive TB cases, all types, registered in 2013 (13) 187
RR-/MDR-TB cases started on second-line treatment in 2012 (56) 9
XDR-TB cases started on second-line treatment in 2012   0
Laboratories 2014  
Smear (per 100 000 population) 1.1
Culture (per 5 million population) 11.0
Drug susceptibility testing (per 5 million population) 0.3
Sites performing Xpert MTB/RIF 2
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2015  
National TB programme budget (US$ millions) 2.2
% Funded domestically 14%
% Funded internationally 0%
% Unfunded 86%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-05-03 Data: www.who.int/tb/data